World Health Organization. Mental health: schizophrenia. World Health Organization. 2022. https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Accessed 24 Apr 2023.

Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115–20. https://doi.org/10.1192/bjp.2021.61.

Article  PubMed  Google Scholar 

Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76. https://doi.org/10.1097/YIC.0b013e32836508e6.

Article  PubMed  Google Scholar 

Masdrakis VG, Baldwin DS. Prevention of suicide by clozapine in mental disorders: systematic review. Eur Neuropsychopharmacol. 2023;69:4–23. https://doi.org/10.1016/j.euroneuro.2022.12.011.

Article  CAS  PubMed  Google Scholar 

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–96. https://doi.org/10.1001/archpsyc.1988.01800330013001.

Article  CAS  PubMed  Google Scholar 

Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62(11):772–7. https://doi.org/10.1177/0706743717718167.

Article  PubMed  PubMed Central  Google Scholar 

Vanasse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand. 2016;134(5):374–84. https://doi.org/10.1111/acps.12621.

Article  CAS  PubMed  Google Scholar 

Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am Journal of Psychiatry. 2016;173(2):166–73. https://doi.org/10.1176/appi.ajp.2015.15030332.

Article  Google Scholar 

Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74(7):686–93. https://doi.org/10.1001/jamapsychiatry.2017.1322.

Article  Google Scholar 

Dong S, Schneider-Thoma J, Bighelli I, Siafis S, Wang D, Burschinski A, et al. A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023. https://doi.org/10.1007/s00406-023-01654-2.

Article  PubMed  Google Scholar 

Psychosis and schizophrenia in adults: prevention and management. National Institute for Health and Care Excellence: Guidelines. London: National Institute for Health and Care Excellence (NICE); 2014.

Barnes TRE, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2019;34(1):3–78. https://doi.org/10.1177/0269881119889296.

Article  PubMed  Google Scholar 

Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aus N Z J Psychiatry. 2016;50(5):410–72. https://doi.org/10.1177/0004867416641195.

Article  Google Scholar 

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. https://doi.org/10.3109/15622975.2012.739708.

Article  PubMed  Google Scholar 

Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong S. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–72. https://doi.org/10.1176/appi.ajp.2020.177901.

Article  PubMed  Google Scholar 

Avasthi A, Sahoo S, Grover S. Clinical practice guidelines for cognitive behavioral therapy for psychotic disorders. Indian J Psychiatry. 2020;62(8):S251–62. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_774_19.

Article  PubMed  PubMed Central  Google Scholar 

Lee JS, Yun J-Y, Kang SH, Lee SJ, Choi J-H, Nam B, et al. Korean medication algorithm for schizophrenia 2019, second revision: treatment of psychotic symptoms. Clin Psychopharmacol Neurosci. 2020;18(3):386–94. https://doi.org/10.9758/cpn.2020.18.3.386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noel JM, Jackson CW. ASHP therapeutic position statement on the use of antipsychotic medications in the treatment of adults with schizophrenia and schizoaffective disorder. Am J Health Syst Pharm. 2020;77(24):2114–32. https://doi.org/10.1093/ajhp/zxaa303.

Article  PubMed  Google Scholar 

Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013;21(1):18–40. https://doi.org/10.1097/HRP.0b013e31827fd915.

Article  PubMed  Google Scholar 

Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–16. https://doi.org/10.1177/0706743717720448.

Article  PubMed  PubMed Central  Google Scholar 

Network SIG. Management of schizophrenia: a national clinical guideline: Scottish Intercollegiate Guidelines Network; 2013.

Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, et al. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013;18(3):150–62. https://doi.org/10.1017/S109285291300014X.

Article  PubMed  Google Scholar 

Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th ed. Wiley; 2021.

Book  Google Scholar 

Verma S, Chan LL, Chee KS, Chen H, Chin SA, Chong SA, et al. Ministry of Health clinical practice guidelines: schizophrenia. Singap Med J. 2011;52(7):521–5 (quiz 6).

CAS  Google Scholar 

Sakurai H, Yasui-Furukori N, Suzuki T, Uchida H, Baba H, Watanabe K, et al. Pharmacological treatment of schizophrenia: Japanese expert consensus. Pharmacopsychiatry. 2021;54(02):60–7.

Article  PubMed  PubMed Central  Google Scholar 

Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses. 2016;10(3):163–77. https://doi.org/10.3371/1935-1232.10.3.163.

Article  PubMed  Google Scholar 

Lee MA, Cola P, Jayathilake K, Meltzer HY. Long-term outcome of clozapine in treatment-resistant schizophrenia. J Clinl Psychopharmacol. 2023;43(3):211–9. https://doi.org/10.1097/jcp.0000000000001671.

Article  CAS  Google Scholar 

Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965–71. https://doi.org/10.1177/0269881108100320.

Article  CAS  PubMed  Google Scholar 

Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51. https://doi.org/10.1111/acps.12742.

Article  CAS  PubMed  Google Scholar 

Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481–5. https://doi.org/10.1192/bjp.bp.111.105833.

Article  PubMed  Google Scholar 

Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv. 2018;69(2):224–7. https://doi.org/10.1176/appi.ps.201700162.

Article  PubMed  Google Scholar 

Farooq S, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJ Psych Bull. 2019;43(1):8–16. https://doi.org/10.1192/bjb.2018.67.

Article  Google Scholar 

Singh B, Hughes AJ, Roerig JL. Comfort level and barriers to the appropriate use of clozapine: a preliminary survey of US psychiatric residents. Acad Psychiatry. 2020;44(1):53–8. https://doi.org/10.1007/s40596-019-01134-7.

Article  PubMed  Google Scholar 

Oloyede E, Blackman G, Mantell B, Harris E, Williams J, Taylor D, et al. What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians. Schizophrenia. 2023;9(1):26. https://doi.org/10.1038/s41537-023-00353-0.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https://doi.org/10.1136/bmj.n160.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267–72.

AGREE Next Steps Consortium. The AGREE II Instrument [Electronic version]. AGREE Next Steps Consortium. 2017. http://www.agreetrust.org. Accessed 8 May 2023.

Berk M, Fitzsimons J, Lambert T, Pantelis C, Kulkarni J, Castle D, et al. Monitoring the safe use of clozapine: a consensus view from Victoria. Australia CNS Drugs. 2007;21(2):117–27. https://doi.org/10.2165/00023210-200721020-00003.

Article  CAS  PubMed  Google Scholar 

World Health Organization. Web Annex A. World Health Organization Model List of Essential Medicines—23rd List, 2023. In: The selection and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24–28 April 2023. Geneva: World Health Organization. 2023. https://iris.who.int/bitstream/handle/10665/371291/WHO-MHP-HPS-EML-2023.01-eng.pdf?sequence=1. Accessed 20 Aug 2023.

Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, et al. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022;36(7):659–79.